Drug Profile
Dimesna - Lantern Pharma
Alternative Names: BNP 7787; LP 300; TavoceptLatest Information Update: 08 May 2023
Price :
$50
*
At a glance
- Originator BioNumerik Pharmaceuticals
- Developer BioNumerik Pharmaceuticals; Lantern Pharma
- Class Alkanesulfonates; Antineoplastics; Chemoprotectants; Small molecules; Sulfhydryl compounds
- Mechanism of Action Glutaredoxin modulators; Thioredoxin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Lung cancer
- Phase II Non-small cell lung cancer
- No development reported Peripheral nervous system diseases